Increased Incidence Of Melanoma Found In Rheumatoid Arthritis Patients Treated With Methotrexate
A chronic, inflammatory disease of unknown origin, rheumatoid arthritis (RA) affects about 1 percent of adults worldwide. Marked by joint destruction, RA often leads to disability and diminished quality of life. It can also lead to an early death from cancer.
Biogen Idec's Baminercept Alfa Shows Promise In Patients With Rheumatoid Arthritis
Biogen Idec presented data on baminercept alfa (BG9924, LT~A
Patients Taking Cymbalta R Reported Reduced Pain Severity Of Osteoarthritis Of The Knee In New Study
New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta (duloxetine HCl) once daily experienced significant pain reduction. Patients taking duloxetine reported significant pain improvement compared to placebo within the first week of treatment that lasted throughout the 13-week trial.
ACTEMRA R tocilizumab Significantly Reduces Rheumatoid Arthritis Signs And Symptoms Regardless Of Previous Therapy In Two New Global Studies
Patients who suffer the chronic and debilitating effects of rheumatoid arthritis (RA) -- despite treatment with current therapies -- achieved significant improvements in signs and symptoms when treated with Roche's ACTEMRA(R) (tocilizumab) alone or in combination with methotrexate compar.
Hand Bone Mineral Density Is An Effective Predictor Of Mortality In Rheumatoid Arthritis
Low bone mineral density in the hand is a valid predictor of overall mortality in patients with rheumatoid arthritis (RA) and indicates long-term prognosis, according to a new study presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.
Biological Medicine Helps More People With Rheumatoid Arthritis
Patients who have recently developed rheumatoid arthritis respond better to treatment with biological medicine in combination with conventional pharmacological medicine. This according to results of the Swefot national clinical study, which is to be presented at an international rheumatology congress in Paris by scientists from Swedish Karolinska Institutet and Karolinska University Hospital, who conducted the study in association with another 15 rheumatology units in Sweden.
Targeted Genetics Announces Positive Phase 1 2 TgAAC94 Data Presented At Annual European Congress Of Rheumatology
Targeted Genetics Corporation (Nasdaq: TGEN) announced that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients refractory to other therapies, including systemic TNF antagonists.
New Self-Management Programme Offers Significant Benefits For Arthritis Patients With Chronic Pain
Adalimumab therapy is effective and well-tolerated in ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients with a previously inadequate response to anti-tumour necrosis factor (anti-TNF) therapies etanercept and infliximab, according to results of research presented today at EULAR 2008, the Annual European Congress of Rheumatology in Paris, France.
New Data Demonstrates Joint Damage Is Inhibited With Wyeth's Biologic Enbrel R Plus Methotrexate In Patients With Early Active Rheumatoid Arthritis
Study Results Provide Further Evidence That Early Treatment of Rheumatoid Arthritis With Enbrel(R) Plus Methotrexate in Moderate to Severe Patients can Stop the Disease From Progressing, and Helps Patients Return to More Normal and Productive Lives Data presented today show that 80% of patients with early active rheumatoid arthritis achieved radiographic remission (or non-progression defined as a change in TSS is less than or equal to 0.
Rigel Initiates Two Phase 2b Clinical Trials Of R788 In Rheumatoid Arthritis
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced the initiation of two Phase 2b clinical trials of its orally bioavailable Syk inhibitor, R788 (fostamatinib disodium), in patients with rheumatoid arthritis (RA). The two clinical trials will be conducted concurrently at a number of clinical research centers throughout the United States, Latin America, and Europe in order to evaluate the efficacy of R788 compared to placebo in distinct RA patient groups.